CDC42 effector protein 3Genealiases: BORG2 · CEP3 · UB1
Q-omics provides the consensus-scored CDC42EP3 profile across patient tissues and cancer cell-line models. CDC42EP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, CDC42EP3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CDC42EP3 RNA expression shows 19,675 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, HNSC, and UVM as cancer lineages where CDC42EP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42EP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42EP3 survival associations across molecular data types. CDC42EP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42EP3 RNA expression–survival associations across cancer types. High CDC42EP3 expression shows unfavorable associations in KIRP, MESO, LGG and DLBC, but favorable associations in SCLC and KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for CDC42EP3 RNA expression.
This table summarizes CDC42EP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC42EP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42EP3 shows lower tumor expression in KIRC, KICH, BLCA and KIRP and higher tumor expression in HNSC and THCA. The HNSC box plot shows higher CDC42EP3 RNA expression in tumor versus normal tissue (log2 FC = +1.447, t-test p < 0.001).
This table shows molecular features associated with CDC42EP3 in patient tissues and cancer cell lines. In patient samples, CDC42EP3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42EP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
